DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Recombinate (Antihemophilic Factor) - Current Clinical Trials

 
 



Recombinate Related Clinical Trials

Russian Kogenate Pediatric Study [Completed]

Pharmacokinetic Comparison of Advate rAHF-PFM With Recombinate rAHF in Patients With Severe Hemophilia A [Completed]

Post Marketing Surveillance To Observe Safety And Efficacy Of Xyntha« In Subjects With Hemophilia A [Completed]

Study Evaluating The Safety Of Xyntha In Usual Care Settings [Terminated]

ADVATE 2 mL Post-Authorization Safety Surveillance (PASS) [Recruiting]

Efficacy and Safety of ADVATE Standard Prophylaxis to Hemophilia A [Not yet recruiting]

Evaluate Efficacy and Safety of ADVATE in the Standard Prophylaxis Treatment of Severe or Moderately Severe Hemophilia A [Not yet recruiting]

Study Evaluating On-Demand Treatment Of Xyntha In Chinese Subjects [Completed]

PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Hemophilia A [Recruiting]

Pharmacokinetic Study of ADVATE 3000 IU in Previously Treated Patients With Severe Hemophilia A [Completed]

Study Evaluating The Efficacy And Safety Of Xyntha In Children Less Than 6 Years Of Age [Terminated]

Relative Bioavailability Of Two Formulations Of Moroctocog Alfa (AF-CC) [Completed]

Study Evaluating Safety And Efficacy Of Moroctocog Alfa (AF-CC) In Previously Treated Hemophilia A Patients [Active, not recruiting]

Study of Safety And Efficacy Of ReFacto AF In Previously Untreated Hemophilia A Patients In The Usual Care Setting [Active, not recruiting]

Study of Prophylaxis, ACtivity and Effectiveness (SPACE) in Hemophilia Patients Currently Treated With ADVATE or RIXUBIS [Recruiting]

BAY79-4980 Compared to rFVIII-FS in Previously Treated Patients With Severe Hemophilia A [Terminated]

Early Prophylaxis Immunologic Challenge (EPIC) Study [Terminated]

Study Evaluating Refacto For Pharmacovigilance [Completed]

Study Evaluating Safety Of Patients Switching To ReFacto AF In Usual Care Settings [Terminated]

China ADVATE PTP Study [Active, not recruiting]

ADVATE Hemophilia A Outcome Database (AHEAD) [Recruiting]

Efficacy and Safety Study of a Recombinant Protein-Free Manufactured Factor VIII (rAHF-PFM) in Previously Untreated Hemophilia A Patients [Completed]

EffeKt Taiwan- Efficacy and Safety of Long-term Treatment With KOGENATE« FS in Taiwan [Completed]

Single Dose Study in Subjects With Severe Hemophilia A Comparing Pharmacokinetic Parameters for BAY81-8973 and Advate [Active, not recruiting]

Trial to Evaluate the Effect of Secondary Prophylaxis With rFVIII Therapy in Severe Hemophilia A Adult and/or Adolescent Subjects Compared to That of Episodic Treatment [Completed]

Study to Establish Bioequivalence of ReFacto AF (BDDrFVIII) With Advate (FLrFVIII) in Hemophilia A [Completed]

A Trial to Compare Prophylaxis Therapy to On-demand Therapy With a New Full Length Recombinant FVIII in Patients With Severe Hemophilia A [Completed]

Study Evaluating Prophylaxis Treatment & Characterizing Efficacy, Safety, & PK Of B-Domain Deleted Recombinant FVIII [Recruiting]

Trial to Evaluate the Efficacy and Safety of a New Full Length Recombinant Human FVIII for Hemophilia A [Completed]

Survey of Inhibitors in Plasma-Product Exposed Toddlers [Recruiting]

EFFEKT - Efficacy and Safety of Long-term Treatment With KOGENATE Bayer/FS [Completed]

Study Investigating a PEGylated Recombinant Factor VIII (BAX 855) for Hemophilia A (PROLONG-ATE Study) [Completed]

BAX 855 Dose-Escalation Safety Study [Completed]

Kogenate FS Regulatory Post-Marketing Surveillance [Completed]

Assessment of the Risk of Inhibitor Formation in Previously Treated Patients With Severe Hemophilia A [Terminated]

International PMS Study - KOGENATE Bayer [Completed]

Study Evaluating Pharmacovigilance Of Refacto AF [Recruiting]

Comparison of the Action of Drugs in the Body and Safety of N8 and Advate´┐Ż in Haemophilia A Subjects [Completed]

Effekt-2 - Efficacy and Safety of Long-term Treatment With KOGENATE« FS in Latin America [Completed]

Study of Pharmacokinetics, Efficacy, and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Pediatric Patients With Hemophilia A [Completed]

Study Evaluating BDDRFVIII and ReFacto AF in Hemophilia A [Completed]

Efficacy and Safety Study of Prophylactic Versus On-Demand Treatment With Feiba NF in Subjects With Hemophilia A or B and a High Titer Inhibitor [Completed]

Study of Safety and Efficacy of Antihemophilic Factor/Von Willebrand Factor Complex in Surgical Subjects With Von Willebrand Disease (vWD) [Completed]

Efficacy and Safety Study of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Pediatric Patients in Canada With Hemophilia A - A Continuation of Baxter Study 060101 [Completed]

Pharmacokinetics, Efficacy and Safety Study of IMMUNATE SD (Human Plasma-Derived Coagulation Factor VIII Concentrate) in Hemophilia A Patients [Completed]

A Single Dose Trial of Recombinant Factor VIII (N8) in Japanese Subjects With Haemophilia A: An Extension to Trial NN7008-3543 [Completed]

Study Evaluating B-Domain Deleted Recombinant Factor VIII (BDDrFVIII, ReFacto AF) in Patients With Hemophilia A Undergoing Elective Major Surgery [Completed]

BAX 855 Pediatric Study [Active, not recruiting]

Expanded Access to B-Domain Deleted Recombinant Porcine Factor VIII (OBI-1) in the Treatment of Acquired Hemophilia A Due to Factor VIII Inhibitory Auto-antibodies [No longer available]

An Open-label Safety, Efficacy and Pharmacokinetic Study of a Recombinant FVIII Compared to Recombinant Human Antihemophilic FVIII in Patients With Severe Hemophilia A [Completed]

Study of the Efficacy of Human Recombinant Factor VIII (Kogenate FS) Reconstituted in Pegylated Liposomes. [Completed]

Prophylaxis Versus On-demand Therapy Through Economic Report [Completed]

BAY14-2222 Continuous Infusion in Surgeries [Completed]

Severe Pregnancy Complications Are Associated With Elevated Factor VIII Plasma Activity [Active, not recruiting]

Efficacy and Safety of Recombinant Factor VIII (GreenGene) in Patients With Hemophilia A [Completed]

Pharmacokinetics, Safety and Efficacy of Recombinant Von Willebrand Factor (rVWF) in the Treatment of Bleeding Episodes in Von Willebrand Disease (VWD) [Completed]

Subclinical Joint Bleeding in Irish Adults With Severe Haemophilia A on Personalised Prophylaxis Regimens [Recruiting]

Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of a Recombinant FVIII in Patients With Severe Hemophilia A [Completed]

Clot Formation and Clot Stability in Patients With Severe Haemophilia A [Completed]

Long-Term Safety and Efficacy of rFVIIIFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia A [Enrolling by invitation]

A Phase III Study on the Safety, Pharmacokinetics and Efficacy of Coagulation Factor VIIa (Recombinant) in Congenital Hemophilia A or B Patients With Inhibitors to Factor VIII or IX [Active, not recruiting]

Safety and Efficacy Study of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients Undergoing Surgery [Completed]

Prospective Biomarkers of Bone Metabolism in Hemophilia A [Not yet recruiting]

Comparative Pharmacokinetic Study of Two Different Strengths of BAY14-2222 [Completed]

Validation Study of a cOmputer Pharmacokinetic Tool to assIst in the Follow up Care of haeMophilia A Patients [Completed]

Genetic Susceptibility to Factor VIII Inhibitors [Completed]

Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Congenital Hemophilia A [Terminated]

Study of First TIME Immunotolerance Induction in Severe Hemophilia A Patients With Inhibitor at High Risk of Failure: Comparison With FVIII Concentrates With or Without Von Willebrand Factor - RES.I.S.T. Naive [Active, not recruiting]

Fc factOrs and Real-World hemophiliA Patient-ReporteD Outcomes [Recruiting]

An Open Label Study to Determine the Safety and Efficacy of Replacement Factor VIII Protein (Known as rFVIIIFc) in Untreated Males With Severe Hemophilia A [Recruiting]

ADVATE Post Authorization Safety Surveillance [Completed]

Activity and Content of Factor VIII (FVIII) in Human Plasma: The Assessment of a Novel Immunoassay [Completed]

Joint Outcome Study Continuation for Children With Severe Factor VIII Deficiency [Enrolling by invitation]

Study of Pharmacokinetics, Efficacy and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients - A Continuation of Clinical Study 069901 [Completed]

Trial to Evaluate the Pharmacokinetics and Safety Profile of BAY94-9027 Following Single and Multiple Dose Administration [Completed]

Phase 3 Efficacy and Safety Study of BAX 855 in Severe Hemophilia A Patients Undergoing Surgical Procedures [Recruiting]

Quality of Life Study of Helixate NexGen [Completed]

Phase 3b Continuation Study of the Safety and Efficacy of Prophylactic BAX 855 in PTPs With Severe Hemophilia A [Recruiting]

Study of Recombinant Porcine Factor VIII (FVIII) in Hemophilia and Inhibitors to FVIII [Completed]

Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Acquired Hemophilia A [Completed]

Pharmacokinetic, Efficacy, and Safety Study of Recombinant Factor VIII Single Chain (rVIII-SingleChain) in Children With Severe Hemophilia A [Active, not recruiting]

Factor XI Levels in Acute Ischemic Stroke [Completed]

Study Evaluating ReFacto in Hemophilia A [Completed]

Effect of Recombinant FVIII in Healthy Male Subjects Treated With TB-402 [Completed]

A Prospective Study to Collect High-Quality Documentation of Bleeds Health-Related Quality of Life (HRQoL), and Safety Outcomes in Patients With Hemophilia A and Factor VIII (FVIII) Inhibitors Treated With Standard-of-Care Treatment [Recruiting]

Pharmacokinetics of rFVIIIFc at Two Vial Strengths [Completed]

Safety/Efficacy Study to Assess Whether FVIII/VWF Concentrate Can Induce Immune Tolerance in Haemophilia A Patients [Recruiting]

Pharmacokinetics and Safety of rFVIIIFc Manufactured at 15,000 L (15K) Scale [Not yet recruiting]

Evaluation Of Acceptability And Satisfaction Of Hemophilia Patients Treated With FusENGO [Recruiting]

To Investigate Safety and Efficacy of NovoEight« (rFVIII) During Long-term Treatment of Haemophilia A in Japan [Recruiting]

A Study With OPTIVATE« in People With Von Willebrand Disease [Terminated]

Health Related Quality of Life of Youth and Young Adults With Hemophilia A [Completed]

An Open Study to Investigate the Safety and Efficacy of Optivate« in Haemophilia A Patients Undergoing Surgery. [Completed]

Efficacy of Alphanate FVIII/VWF Concentrate in Type 3 Von Willebrand Patients [Recruiting]

Covalent Tolerance Induction to Factor VIII-Prediction of Inhibitors in Hemophilia [Recruiting]

Prophylaxis Versus on Demand Treatment for Children With Hemophilia A [Completed]

Combination Therapy of Low Doses of rFVIIa and FEIBA for Severe Hemophilia A Patients With an Inhibitor to Factor VIII [Completed]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015